{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.7","upperLimit":"99.3","value":"95.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Rate of participants' survival at time of evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"80 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion\n\nMelphalan: Melphalan 100 mg/m\\^2 IV over 30-45 minutes.\n\nDexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).\n\nAutologous Hematopoietic Cell Transplantation (HCT): Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.\n\nFosaprepitant: Fosaprepitant at 150 mg IV on days -3 and -2.","id":"OG000","title":"Phase 1 Dose Level 3 and Phase 2: Selinexor Plus HDM HCT"}],"paramType":"NUMBER","populationDescription":"All evaluable participants treated at dose level 3/RP2D.","reportingStatus":"POSTED","timeFrame":"at 24 months","title":"Overall Survival (OS)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percent"}